Beside CZE, another kind of CE method, capillary isoelectric focusing (CIEF) applied on Helena V8 platform E-class has also been used in thalassemia screening now. And there is recent study agree that CIEF has good performance in hemoglobinopathy screening and good correlation with CZE and HPLC. 4 Due to several possible mechanisms especially by natural selection, thalassemia is an extremely heterogeneous distribution disease that quite different incidence and types of hemoglobin variants can be found in different areas. 5 southern China is an area suffers from thalassemia heavily where very high thalassemia gene frequencies can be identified in many provinces, for example 0.01%-3.17% (α-thalassemia) and 1.60%-3.56% (β-thalassemia) of the population in Sichuan, 3.18%-9.46% (α-thalassemia) and 1.60%-3.56% (β-thalassemia) in Guangdong and 9.47%-14.13% (α-thalassemia) and 3.57%-6.78% (β-thalassemia)
in Guangxi, 6 etc. In these territories, instead of Hb S which is the most common variant in Europeans and Americans, Hb E and Hb Constant Spring (Hb CS) become the top 2 variants related to β gene abnormity, together with Hb H and/or Hb Barts which are related to α gene abnormity, and form the most essential group of variants which should be identified carefully during hemoglobinopathy screening in southern China. [6] [7] [8] [9] This situation requires methods or instruments used in southern China having the ability to identify trace peaks and distinguish abnormal peaks from normal peaks. So in this study, the performance of CIEF equipment Helena V8 platform E-class and CZE equipment Sebia Minicap on identifying Hb E, Hb CS, Hb H and Hb
Barts for patients from southern China was compared.
| MATERIAL S AND ME THODS

| Patients and specimens
All patients were Han Chinese settling in Sichuan province. Their demographic and genetic information was collected.
For Hb E evaluation, totally 5 specimens from patients with β thalassemia mutations (G > A at codon 26, both heterozygote and homozygote) identified by the RDB (reverse dot blot) assay were analyzed by both Minicap and Helena V8 at same time within 3 days after sampling.
For Hb CS evaluation, totally 8 specimens from patients with α thalassemia mutations (TAA > CAA at codon 142, both heterozygote and homozygote) identified by the RDB (reverse dot blot) assay were analyzed by both Minicap and Helena V8 at same time within 3 days after sampling.
For Hb H and Hb Barts evaluation, totally 10 specimens from patients with α thalassemia mutations identified by the Gap-PCR assay (3 known deletional forms of a thalassemia -SEA /, -a 3.7 , -a 4.2 were detected) were analyzed by both Minicap and Helena V8 at same time within 3 days after sampling. 
| Equipments, reagents, and data recoding and analysis
| Lowest detection limits confirm
In order to confirm the ability of capillary electrophoresis analyzers to identify trace peaks, which is a very essential function in Hb CS 
| RE SULTS
| Hb E analysis
Results of all specimens analyzed by Helena V8 showed fusion peaks of Hb E and Hb A2, while under the same conditions, Sebia Minicap made clear distinctions between peaks of Hb E and Hb A2, as shown in Figure 1 below. Although Helena V8 could not distinguish peaks of Hb E from Hb A2 just like Sebia Minicap did, the consistency still could be found between Helena V8 and Sebia Minicap in Hb E+ Hb A2 quantifying (All bias were lower than 15%, the results of Sebia Minicap as targets). Results and information of patients are shown in Table 1 below. On the other hand, when samples were analyzed by Sebia Minicap, 
| Hb H and Hb Barts analysis
| Hb CS analysis
Only a part of the patients (3 of 8, 37.5%) with Hb CS could be screened out by Helena V8. However, on the other hand, all patients could be identified by Sebia Minicap. And even for those that Hb CS indentified by both methods, Sebia Minicap showed more clear distinctions between peaks than Helena V8 which might only show a wider and longer irregular fusion peak (Hb A2 and Hb CS), as shown in Figure 3 below. Like results of Hb E analysis, the consistency could be found between Helena V8 and Sebia Minicap in Hb CS+ Hb A2 quantifying (All bias were lower than 15%, the results of Sebia Minicap as targets).
Results and information of patients are shown in Table 3 below. 
| Lowest detection limits
In order to evaluate the ability of Helena V8 and Sebia Minicap to identify trace peaks, 2 samples were chosen: Sample A was from a newborn sampling within 24 hours after birth, that had its Hb A2% near to 0 (A%); sample B was form a β thalassemia patients that had a lower HB A2 level (B%). Two samples were mixed together in different volumes (vA1, vA2, vA3, vA4, vA5, and vA6; vB1, vB2, vB3, vB4, vB5 , and vB6) and tested twice by Helena V8 and Sebia Minicap, respectively, and then, the mean of 2 results of each mixture and the corresponding best-fit target were used to work out difference (best-fit as target). The "best-fit" target was calculated by formula, for example, best-fit target 1 = (A%*vA1 + B%*vB1)/(vA1 + vB1).
Mixing volumes, testing results, best-fit values, and bias of Helena V8 are shown in Table 4 , while Sebia Minicap is shown in Table 5 and the data of linear regression (Sebia Minicap, 0.2%-1.46%, r 2 = .9901, Helena V8, 0.6%-1.35%, r 2 = .9971) are shown in Figure 4 .
As the data shown, Sebia Minicap had a lower detection limit for trace peaks than Helena V8 that even when Hb A2% decreased near to 0.1%, still the peaks could be quantified by Sebia Minicap.
And Helena V8 was dwarfed by these good performances of Sebia Minicap, as, in Helena V8, no peaks could be indentified until the level of Hb A2% reached near to 0.6%. β-thalassemia diagnosis for adults. Because Hb A2 (whether normal or abnormal) will not exceed 8%, 9 it is not difficult to indentify Hb E when there is a peak located in the area of Hb A2 with the percentage higher than 8%. But as shown in 
| D ISCUSS I ON
